Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Comparison of Survival Outcomes Between Partial Resection and Biopsy for Primary Glioblastoma: A Propensity Score-Matched Study.

Byun J, Kim YH, Nam SJ, Park JE, Cho YH, Kim HS, Hong SH, Kim JH, Kim SJ, Kim CJ.

World Neurosurg. 2019 Jan;121:e858-e866. doi: 10.1016/j.wneu.2018.09.237. Epub 2018 Oct 11.

PMID:
30315970
2.

MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.

Kim YS, Kim SH, Cho J, Kim JW, Chang JH, Kim DS, Lee KS, Suh CO.

Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):661-7. doi: 10.1016/j.ijrobp.2011.12.086. Epub 2012 Mar 11.

PMID:
22414280
3.

Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients.

Salvati M, Pichierri A, Piccirilli M, Floriana Brunetto GM, D'Elia A, Artizzu S, Santoro F, Arcella A, Giangaspero F, Frati A, Simione L, Santoro A.

J Neurosurg. 2012 Aug;117(2):204-11. doi: 10.3171/2012.4.JNS101702. Epub 2012 Jun 1.

PMID:
22655594
4.

Positive influence of partial resection on overall survival of patients with overlapping glioblastomas.

Quick-Weller J, Tritt S, Baumgarten P, Konczalla J, Kashefiolasl S, Noack A, Tichy J, Seifert V, Marquardt G.

Clin Neurol Neurosurg. 2017 Oct;161:22-28. doi: 10.1016/j.clineuro.2017.06.021. Epub 2017 Jun 29.

PMID:
28837843
5.

One decade of glioblastoma multiforme surgery in 342 elderly patients: what have we learned?

Heiland DH, Haaker G, Watzlawick R, Delev D, Masalha W, Franco P, Machein M, Staszewski O, Oelhke O, Nicolay NH, Schnell O.

J Neurooncol. 2018 Nov;140(2):385-391. doi: 10.1007/s11060-018-2964-8. Epub 2018 Aug 3. Erratum in: J Neurooncol. 2018 Sep 10;:.

PMID:
30076585
6.

Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.

Barbagallo GM, Paratore S, Caltabiano R, Palmucci S, Parra HS, Privitera G, Motta F, Lanzafame S, Scaglione G, Longo A, Albanese V, Certo F.

Neurosurg Focus. 2014 Dec;37(6):E4. doi: 10.3171/2014.9.FOCUS14502.

PMID:
25434389
7.

Pre-Operative Perfusion Skewness and Kurtosis Are Potential Predictors of Progression-Free Survival after Partial Resection of Newly Diagnosed Glioblastoma.

Paik W, Kim HS, Choi CG, Kim SJ.

Korean J Radiol. 2016 Jan-Feb;17(1):117-26. doi: 10.3348/kjr.2016.17.1.117. Epub 2016 Jan 6.

8.

Early postoperative tumor progression predicts clinical outcome in glioblastoma-implication for clinical trials.

Merkel A, Soeldner D, Wendl C, Urkan D, Kuramatsu JB, Seliger C, Proescholdt M, Eyupoglu IY, Hau P, Uhl M.

J Neurooncol. 2017 Apr;132(2):249-254. doi: 10.1007/s11060-016-2362-z. Epub 2017 Jan 18.

9.

Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.

Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, Gilbert MR, Herndon JE 2nd, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling RJ, Shi W, Vredenburgh JJ, Bigner DD.

J Clin Oncol. 2010 Nov 1;28(31):4722-9. doi: 10.1200/JCO.2010.28.6963. Epub 2010 Oct 4.

10.

Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: A single-center analysis.

Roh TH, Park HH, Kang SG, Moon JH, Kim EH, Hong CK, Ahn SS, Choi HJ, Cho J, Kim SH, Lee SK, Kim DS, Kim SH, Suh CO, Lee KS, Chang JH.

Medicine (Baltimore). 2017 Jul;96(27):e7422. doi: 10.1097/MD.0000000000007422.

11.

Evaluating extent of resection in pediatric glioblastoma: a multiple propensity score-adjusted population-based analysis.

Adams H, Adams HH, Jackson C, Rincon-Torroella J, Jallo GI, QuiƱones-Hinojosa A.

Childs Nerv Syst. 2016 Mar;32(3):493-503. doi: 10.1007/s00381-015-3006-x. Epub 2016 Jan 15.

PMID:
26767842
12.

The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study.

Rapp M, Goeppert M, Felsberg J, Steiger HJ, Sabel M.

Br J Neurosurg. 2013 Aug;27(4):430-5. doi: 10.3109/02688697.2013.767317. Epub 2013 Feb 18.

PMID:
23418781
13.

The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials.

Binabaj MM, Bahrami A, ShahidSales S, Joodi M, Joudi Mashhad M, Hassanian SM, Anvari K, Avan A.

J Cell Physiol. 2018 Jan;233(1):378-386. doi: 10.1002/jcp.25896. Epub 2017 May 16. Review.

PMID:
28266716
14.

Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience.

Pessina F, Navarria P, Cozzi L, Ascolese AM, Simonelli M, Santoro A, Clerici E, Rossi M, Scorsetti M, Bello L.

J Neurooncol. 2017 Oct;135(1):129-139. doi: 10.1007/s11060-017-2559-9. Epub 2017 Jul 8.

PMID:
28689368
15.

Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide.

Minniti G, Salvati M, Arcella A, Buttarelli F, D'Elia A, Lanzetta G, Esposito V, Scarpino S, Maurizi Enrici R, Giangaspero F.

J Neurooncol. 2011 Apr;102(2):311-6. doi: 10.1007/s11060-010-0324-4. Epub 2010 Aug 5.

PMID:
20686820
16.

Patient outcomes following second surgery for recurrent glioblastoma.

Brandes AA, Bartolotti M, Tosoni A, Poggi R, Bartolini S, Paccapelo A, Bacci A, Ghimenton C, Pession A, Bortolotti C, Zucchelli M, Galzio R, Talacchi A, Volpin L, Marucci G, de Biase D, Pizzolitto S, Danieli D, Ermani M, Franceschi E.

Future Oncol. 2016;12(8):1039-44. doi: 10.2217/fon.16.9. Epub 2016 Feb 16.

PMID:
26880307
17.
18.

Effect of pretreatment clinical factors on overall survival in glioblastoma multiforme: a Surveillance Epidemiology and End Results (SEER) population analysis.

Thumma SR, Fairbanks RK, Lamoreaux WT, Mackay AR, Demakas JJ, Cooke BS, Elaimy AL, Hanson PW, Lee CM.

World J Surg Oncol. 2012 May 3;10:75. doi: 10.1186/1477-7819-10-75.

19.

Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome.

Lalezari S, Chou AP, Tran A, Solis OE, Khanlou N, Chen W, Li S, Carrillo JA, Chowdhury R, Selfridge J, Sanchez DE, Wilson RW, Zurayk M, Lalezari J, Lou JJ, Ormiston L, Ancheta K, Hanna R, Miller P, Piccioni D, Ellingson BM, Buchanan C, Mischel PS, Nghiemphu PL, Green R, Wang HJ, Pope WB, Liau LM, Elashoff RM, Cloughesy TF, Yong WH, Lai A.

Neuro Oncol. 2013 Mar;15(3):370-81. doi: 10.1093/neuonc/nos308. Epub 2013 Jan 17.

20.

Clinical correlation of MGMT protein expression and promoter methylation in Chinese glioblastoma patients.

Tang K, Jin Q, Yan W, Zhang W, You G, Liu Y, Jiang T.

Med Oncol. 2012 Jun;29(2):1292-6. doi: 10.1007/s12032-011-9901-4. Epub 2011 Mar 11.

PMID:
21394635

Supplemental Content

Support Center